
Tuesday, March 09, 2021 5:28:47 PM
Recent MNOV News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/19/2025 09:55:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 09:54:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 09:52:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 09:51:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 09:50:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 09:49:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 09:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 09:00:21 PM
- MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND • GlobeNewswire Inc. • 12/05/2024 11:00:00 PM
- MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders • GlobeNewswire Inc. • 11/19/2024 02:00:00 PM
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver • GlobeNewswire Inc. • 11/14/2024 11:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2024 09:17:03 PM
- MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis • GlobeNewswire Inc. • 11/11/2024 11:00:00 PM
- MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) • GlobeNewswire Inc. • 10/23/2024 11:00:00 PM
- MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) • GlobeNewswire Inc. • 09/30/2024 01:00:00 PM
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND • GlobeNewswire Inc. • 09/09/2024 11:00:00 PM
- MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting • GlobeNewswire Inc. • 09/03/2024 11:00:00 PM
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition • GlobeNewswire Inc. • 08/29/2024 11:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:32:00 PM
- MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations • GlobeNewswire Inc. • 06/20/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 11:41:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 11:40:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 11:40:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:15:10 PM
- MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer • GlobeNewswire Inc. • 06/05/2024 10:00:00 AM
FEATURED Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 • Mar 10, 2025 9:05 AM
North Bay Resources Announces Assays up to 5.69% Copper, 1 Opt. Silver, and 0.22% Vanadium at Copper Island Project, British Columbia • NBRI • Mar 10, 2025 9:00 AM
Avant Technologies and JV Partner, Ainnova, Strategically Align with Apollo Hospitals to Advance AI in Healthcare • AVAI • Mar 10, 2025 8:00 AM
Veri Medtech (VRHI) Network Grows To 400 Physicians • VRHI • Mar 10, 2025 7:32 AM
One World Products' Isiah Thomas Issues Investor Update • OWPC • Mar 6, 2025 9:19 AM
Authentic Holdings To Reduce Debt by over $2 Million While Achieving Substantial Revenue Growth • AHRO • Mar 6, 2025 8:00 AM